What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2025-02-24 compared with 2024-03-08 · 52 added, 14 removed, 19 unchanged (78% of the section changed)

17 unchanged sentences

Fourth Quarter

March 8, 2024, the Company had 106,551,722 outstanding shares of common stock and 144 shareholders of record.

of common stock are entitled to receive dividends as may be declared by the Company’s Board.

The Company’s Board is not restricted

from paying any dividends but is not obligated to declare a dividend.

No dividends have ever been declared, and it is not anticipated

that dividends will be paid in the foreseeable future.

Any indebtedness the Company incurs in the future may also limit its ability to

pay dividends.

Investors should not purchase the Company’s common stock with the expectation of receiving cash dividends.

Sales of Unregistered Securities

were no sales of unregistered securities during the fourth quarter of the fiscal year ended September 30, 2023.

of Equity Securities by the Issuer and Affiliated Purchasers

did not repurchase any securities during the fourth quarter of the fiscal year ended September 30, 2023.

February 24, 2025 , the Company had 113,951,722 outstanding

shares of common stock and 143 shareholders of record.

Holders of common stock are entitled

to receive dividends as may be declared by the Company’s Board.

The Company’s Board is not restricted from paying any dividends

but is not obligated to declare a dividend.

No dividends have ever been declared, and it is not anticipated that dividends will be paid

in the foreseeable future.

Any indebtedness the Company incurs in the future may also limit its ability to pay dividends.

Investors should

not purchase the Company’s common stock with the expectation of receiving cash dividends.

Recent Sales of Unregistered Securities

In May 2024, the Company issued 750,000 shares of

its common stock to an accredited investor for $15,000 in gross proceeds.

The issuance to the investor relied on the exemption from registration provided

by Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereunder concerning the issuance of restricted

In May 2024, the Company issued 1,000,000 shares of its common stock to a

lender as a commitment fee.

The fair market value of the common stock on the date of grant was $70,000.

The issuance to the investor relied

on the exemption from registration provided by Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation

D promulgated thereunder concerning the issuance of restricted

In July 2024, the Company issued 400,000 shares of

its common stock to four accredited investors for $8,000 in gross proceeds.

The issuance to the investor relied on the exemption from registration provided

by Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereunder concerning the issuance of restricted

On July 12, 2024, the Company sold a warrant to purchase

5,000,000 shares of the Company’s common stock at an exercise price of $0.00001 to an investor for $50,000.

The warrant has no expiration

The investor has the option of funding the Company with two additional tranches of $50,000.

The second tranche of $50,000 is due

within 60 days of the first funding date of July 12, 2024.

On August 19, 2024, the Company received the funding

for the second tranche and issued to the investor a cash warrant to purchase up to 666,666 shares of Common Stock at an exercise price

of $0.08 per share.

The warrant has no expiration date.

In November 2024, the Company issued 250,000 shares

of its common stock to an accredited investor for $5,000 in gross proceeds.

The issuance to the investor relied on the exemption from registration provided

by Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereunder concerning the issuance of restricted

At any time 90 days after the second tranche funding

date the investor may invest an additional $50,000 and the Company will issue to the investor a pre-funded warrant to purchase up to 2,500,000

shares of Common Stock in the and a cash warrant to purchase up to 333,333 shares of Common Stock at an exercise price of $0.08 per share.

The warrant does not have an expiration date.

The issuance to the investor relied on the exemption from registration provided

by Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereunder concerning the issuance of restricted

Purchase of Equity Securities by the Issuer

and Affiliated Purchasers

We did not repurchase any securities

during the fiscal year ended September 30, 2024.

Selected Financial Data

a smaller reporting company, we are not required to provide the information required by this Item.

As a smaller reporting company,

we are not required to provide the information required by this Item.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity